Clinical Trials Logo

Chronic Heart Disease clinical trials

View clinical trials related to Chronic Heart Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT06137430 Not yet recruiting - Clinical trials for Chronic Heart Disease

Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure

Start date: December 1, 2023
Phase:
Study type: Observational

To evaluate the efficacy of SGLT2 inhibitors on left ventricular global longitudinal strain and diastology parameters among diabetic and non-diabetic patients with chronic heart failure

NCT ID: NCT03966729 Recruiting - Heart Failure Clinical Trials

Relationships and Differences Analysis in Heart Failure

REDEAL-HF
Start date: January 1, 2009
Phase:
Study type: Observational

This study characterizes heart failure patients who attended the University Hospital Würzburg. The primary aim is a better understanding of the relationships and differences between the subgroups HFrEF (EF < 40%), HFmrEF (EF 40-49%), and HFpEF (EF>50%), contributing to an improved diagnosis, prognosis and therapy of patients with heart failure.

NCT ID: NCT03773991 Completed - Clinical trials for End Stage Renal Disease

Dyspnea Assessment in Hemodialysis Patients

Start date: March 29, 2019
Phase:
Study type: Observational

Shortness of breath is very common among patients on dialysis for kidney failure; however, its causes are often not understood. This study will explore the lungs and the heart of these patients to determine the causes of shortness of breath. The amount of salt in the body tissues, which tends to accumulate in dialysis patients and can also cause shortness of breath, will also be measured. Machines that exploit magnetic resonance, ultrasound and x-rays to take images of the body interior will be employed; in addition, breathing tests, questionnaires and blood tests will also be used. 20 patients on dialysis will be recruited and have two visits: one at the beginning of the study and one year later to observe any changes in the lungs, heart and salt accumulation over time.

NCT ID: NCT03339310 Completed - Heart Failure Clinical Trials

Evaluation of the Safety and Efficacy of the 2-lead OPTIMIZER® Smart System

FIX-HF-5C2
Start date: October 23, 2017
Phase: N/A
Study type: Interventional

This is a multicenter, prospective, single-arm study of the Optimizer Smart System with 2-leads

NCT ID: NCT03102437 Terminated - Heart Failure Clinical Trials

Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System

FIX-HF-5CA
Start date: July 1, 2017
Phase: N/A
Study type: Interventional

This is a multicenter, prospective, single-arm Continued Access study of the Optimizer Smart System with CCM therapy.

NCT ID: NCT03018717 Active, not recruiting - Clinical trials for Chronic Lung Disease

Integral Clinical Plan Shared With or Without Telemonitoring of Constants in Patient With Chronic Diseases

ATLAN_TIC01
Start date: June 13, 2016
Phase: N/A
Study type: Interventional

Information and communications technologies (ICT) currently constitute a key element in the innovation and improvement of providing health-care to frail populations with advanced chronic diseases, but it´s efficacy, safety and cost-effectiveness has not yet been proven conclusively. The investigators are going to carry out a multi-center, randomized, parallel groups, phase III clinical trial in adult patient with heart and/or lung advanced diseases,aiming to analyze the efficacy and cost-efficacy of tele-monitorization of bio-parameters added to optimal standard of clinical care (shared clinical care plan) compared to the shared clinical care plan exclusively.

NCT ID: NCT01032395 Completed - Diabetes Mellitus Clinical Trials

Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

Start date: March 2010
Phase: Phase 3
Study type: Interventional

This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of A(H1N1) inactivated influenza virus vaccine in subjects with Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus, and to compare safety and immunogenicity data with a contemporaneously enrolled control group of age-comparable, healthy subjects. Because certain individuals may be hypo-responsive to influenza vaccination, additional studies with high-risk groups are warranted in order to determine the optimal vaccine formulation and dosing schedule for prevention of novel H1N1 virus infection.